ICLR
ICON Public Limited Company
There isn't enough reported data to score ICLR yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
ICLR Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Healthy | |
| Stable |
ICLR's revenue and cash flow are currently healthy, and its profitability and balance sheet are stable.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
ICLR PE Valuation
ICLR has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
ICLR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Stable | |
| Stable | |
| Limited | |
| High |
Analysts expect ICLR's earnings, revenue and profitability to hold roughly steady.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
ICLR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $11.26 | +288% |
| Q4 2025 | $2.90 | -70% |
| Q3 2025 | $7.39 | -18% |
| Q2 2025 | $9.72 | +13% |
| Q1 2025 | $9.18 | +11% |
| Q4 2024 | $9.53 | +29% |
| Q3 2024 | $8.99 | +45% |
| Q2 2024 | $8.60 | +39% |
| Q1 2024 | $8.24 | +33% |
NVO has the stronger earnings trend. Trailing diluted EPS is down 70% for ICLR versus NVO up 4.9%.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
ICLR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2B | -0.9% |
| Q2 2026 | $2.1B | +2.3% |
| Q1 2026 | $2B | +1.6% |
| Q4 2025 | $8.3B | +304% |
| Q3 2025 | $2B | +0.6% |
| Q2 2025 | $2B | -4.8% |
| Q1 2025 | $2B | -4.3% |
| Q4 2024 | $2B | -1.2% |
ICLR's revenue has picked up after three years of holding roughly level: $2B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 9.8% | +5.6 points |
| Q2 2026 | 6.7% | -3.7 points |
| Q1 2026 | 8.5% | -2.4 points |
| Q4 2025 | 5.4% | -9.2 points |
| Q3 2025 | 4.2% | -9.8 points |
| Q2 2025 | 10% | -0.5 points |
| Q1 2025 | 11% | -2.7 points |
| Q4 2024 | 15% | +1.7 points |
ICLR's operating margin was 9.8% last quarter, up 5.6 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over ICLR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over ICLR on profitability, with a higher operating margin.
ICLR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $307.1M | -8% |
| Q2 2026 | $238.8M | +110% |
| Q1 2026 | $136.2M | -43% |
| Q4 2025 | $862M | +211% |
| Q3 2025 | $333.9M | -7.1% |
| Q2 2025 | $113.9M | -38% |
| Q1 2025 | $239.3M | -20% |
| Q4 2024 | $277M | -28% |
ICLR generated $1.5B in free cash flow over the past year, up 60% from the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over ICLR on cash flow, with more consistent year-over-year improvement.
ICLR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +32.7K shares |
| 1 year | -0.9% | -678K shares |
| 3 years | -6.7% | -5.6M shares |
| 5 years | -4.2% | -3.4M shares |
| Available history | +42% | +23.1M shares |
ICLR has the edge over NVO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $400M |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | $750M |
| Q3 2025 | $250M |
| Q2 2025 | $250M |
| Q1 2025 | $250M |
| Q4 2024 | $400M |
ICLR spent $1.1B buying back its own shares over the past year, about the same as the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has 4.4B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
ICLR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | 2.7x | Moderate |
| Q3 2025 | 2.0x | Moderate |
| Q2 2025 | 2.2x | Moderate |
| Q1 2025 | 2.0x | Healthy |
| Q4 2024 | 1.8x | Healthy |
| Q3 2024 | 1.7x | Healthy |
| Q2 2024 | 1.8x | Healthy |
| Q1 2024 | 1.9x | Healthy |
ICLR's net debt is about 2.7 years of its operating earnings (EBITDA), up from 1.8 years a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
ICLR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 65.0 | Neutral |
| Stochastic | 79.3 | Neutral |
ICLR's weekly RSI is 65 (neutral) and its Stochastic is 79 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
ICLR PE vs Healthcare Sector
| Metric | ICLR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ICLR has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ICLR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $183.8 | 9.1% above |
| 20 week MA | $173.9 | 15% above |
| 50 week MA | $152.9 | 31% above |
| 100 week MA | $161.8 | 24% above |
| 200 week MA | $213.5 | 6.1% below |
ICLR has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
ICLR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $171.9 | $192.5 | +12% |
| 2021 | $192.5 | $307.9 | +60% |
| 2022 | $307.9 | $194.9 | -37% |
| 2023 | $194.9 | $283.1 | +45% |
| 2024 | $283.1 | $212.3 | -25% |
| 2025 | $212.3 | $182.8 | -14% |
| 2026 YTD | $182.8 | $200.5 | +9.7% |
ICLR has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.